MarginsXMarginsX
Home › Markets › Health Care › RNTX

Rein Therapeutics Inc. (RNTX)

RNTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.4000
-27.55% on the day
Market cap
$34.5M
Nano cap
Revenue · 2025
$0
Prior year not contiguous
Net income · 2025
-$49.9M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1420565/000119312526126385/0001193125-26-126385-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerRNTX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2017
SEC CIK0001420565
SEC industry codePharmaceutical Preparations
Incorporated inDELAWARE

Financials · 2025

LineValue
Revenue$0
Net income-$49.9M
Operating income-$50.6M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$3.2M
Total assets$24.2M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
5.4 months
$8.5M cash at June 30, 2026
Share count, 1 year
+270.2%
2025-08-11 to 2026-08-12 · +1799.7% over 3 years
Going-concern doubt
No
10-Q filed August 14, 2026
Insider net buying, 12 months
$625K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-08-14
Cash and burn$8.5M cash; operating cash flow -$4.7M a quarter.Report 2026-06-30
Shares outstanding86,267,032 (2026-08-12); 23,305,108 a year earlier; 4,541,167 three years earlier.Cover page 2026-08-12
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-05-04
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-08-27
AuditorCBIZ CPAs P.C., New York, New York, United States; changed auditors 1 time in 24 months8-K 4.01 2025-04-17
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $625K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$0-$6.4M-$8.6M$8.5MNo debt tags$010-Q 2026-08-14
Q1 2026
2026-03-31
$0-$5.8M-$3.4M$4.4M$4.9M$010-Q 2026-05-15
Q4 2025
2025-12-31
$0-$32.0M-$3.2M$3.2M$0$010-K 2026-03-26
Q3 2025
2025-09-30
$0-$5.6M-$3.5M$4.0MNo debt tags$010-Q 2025-11-14
Q2 2025
2025-06-30
$0-$6.8M-$6.4M$5.7MNo debt tags$010-Q 2026-08-14
Q1 2025
2025-03-31
$0-$5.5M-$6.2M$7.4MNo debt tags$010-Q 2026-05-15
Q4 2024
2024-12-31
$0-$41.0M-$4.8M$12.9MNo debt tags$010-K 2026-03-26
Q3 2024
2024-09-30
$0-$5.8M-$3.8M$17.7MNo debt tags$010-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-05-04
Latest annual report10-K/A2026-04-27
Latest quarterly / interim10-Q2026-11-16
Latest current report8-K2026-11-16
Latest proxyDEFA14A2026-06-08

Source: SEC EDGAR submissions feed, 527 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-10.1%
1 month-26.9%
3 months-29.9%
Year to date-52.4%
1 year-59.1%
From 52-week high-70.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
OSTXOS Therapies Incorporated$0.6807-8.63%$35.4M
TELOTelomir Pharmaceuticals Inc.$0.4810-1.96%$35.4M
VERUVeru Inc.$2.08-0.48%$35.5M
ATHEAlterity Therapeutics Limited$1.960.00%$35.7M
GRCEGrace Therapeutics Inc.$1.75-3.31%$36.8M
NNVCNanoViricides Inc.$1.24+0.81%$31.7M
SERSerina Therapeutics Inc.$1.42+2.16%$37.7M
BMEABiomea Fusion Inc.$0.5201-10.67%$37.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier